Frankfurt - Delayed Quote EUR

Scholar Rock Holding Corporation (2QK.F)

12.90

+0.10

(+0.78%)

As of 8:13 AM GMT+2. Market Open.

Advanced Chart

Loading Chart for 2QK.F

9/21 12:03 PM

DELL

Previous Close 12.80
Open 12.90
Bid 12.90 x --
Ask 13.50 x --
Day's Range 12.90 - 12.90
52 Week Range 5.35 - 18.30
Volume 100
Avg. Volume 86
Market Cap (intraday) 1.032B
Beta (5Y Monthly) 0.89
PE Ratio (TTM) --
EPS (TTM) -1.87
Earnings Date May 7, 2024 - May 13, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 63.25

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

scholarrock.com

150